5.36
-0.02 (-0.37%)
| Previous Close | 5.38 |
| Open | 5.39 |
| Volume | 6,693 |
| Avg. Volume (3M) | 139,225 |
| Market Cap | 29,444,410 |
| Price / Sales | 0.650 |
| Price / Book | 28.85 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 |
| Profit Margin | -146.93% |
| Operating Margin (TTM) | -557.51% |
| Diluted EPS (TTM) | -15.27 |
| Quarterly Revenue Growth (YOY) | -54.00% |
| Current Ratio (MRQ) | 0.100 |
| Operating Cash Flow (TTM) | 15.96 M |
| Levered Free Cash Flow (TTM) | 42.76 M |
| Return on Assets (TTM) | -69.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bearish | Mixed |
| Drug Manufacturers - General (Global) | Bearish | Mixed | |
| Stock | Scilex Holding Company | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Small Value |
| % Held by Insiders | 22.38% |
| % Held by Institutions | 18.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| E Fund Management Co., Ltd. | 31 Mar 2025 | 31,431 |
| Rafferty Asset Management, Llc | 31 Mar 2025 | 17,717 |
| Klp Kapitalforvaltning As | 31 Mar 2025 | 10,212 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |